TBX3 is overexpressed in breast cancer and represses p14ARF by interacting with histone deacetylases

Cancer Research

Volumn 68, Issue 3, 2008, Pages 693-699

  Yarosh, Will ^a   Barrientos, Tomasa ^a,c   Esmailpour, Taraneh ^a   Lin, Limin ^a   Carpenter, Philip M ^a   Osann, Kathryn ^a   Anton Culver, Hoda ^a   Huang, Taosheng ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; BIOLOGICAL MARKER; CYCLIN DEPENDENT KINASE INHIBITOR 2A; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE INHIBITOR; LUCIFERASE; T BOX TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR TBX3; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL CELL; ARTICLE; BINDING SITE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER TISSUE; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ENZYME REPRESSION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN LOCALIZATION;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; COS CELLS; FEMALE; HISTONE DEACETYLASES; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; MIDDLE AGED; PROMOTER REGIONS (GENETICS); PROTEIN STRUCTURE, TERTIARY; T-BOX DOMAIN PROTEINS; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P14ARF; UP-REGULATION;

EID: 38849139136     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-5012     Document Type: Article

References (28)

1. Bamshad M, Lin RC, Law DJ, et al. Mutations in human TBX3 alter limb, apocrine and genital development in ulnar-mammary syndrome. Nat Genet 1997;16:311-5.
2. Carlson H, Ota S, Campbell CE, Hurlin PJ. A dominant repression domain in Tbx3 mediates transcriptional repression and cell immortalization: relevance to mutations in Tbx3 that cause ulnar-mammary syndrome. Hum Mol Genet 2001;10:2403-13.
3. Bamshad M, Le T, Watkins WS, et al. The spectrum of mutations in TBX3: genotype/phenotype relationship in ulnar-mammary syndrome. Am J Hum Genet 1999;64:1550-62.
4. Jerome-Majewska LA, Jenkins GP, Ernstoff E, Zindy F, Sherr CJ, Papaioannou VE. Tbx3, the ulnar-mammary syndrome gene, and Tbx2 interact in mammary gland development through a p19Arf/p53-independent pathway. Dev Dyn 2005;234:922-33.
5. Davenport TG, Jerome-Majewska LA, Papaioannou VE. Mammary gland, limb and yolk sac defects in mice lacking Tbx3, the gene mutated in human ulnar mammary syndrome. Development 2003;130:2263-73.
6. Rowley M, Grothey E, Couch FJ. The role of Tbx2 and Tbx3 in mammary development and tumorigenesis. J Mammary Gland Biol Neoplasia 2004;9:109-18.
7. Fan W, Huang X, Chen C, Gray J, Huang T. TBX3 and its isoform TBX3+2a are functionally distinctive in inhibition of senescence and are overexpressed in a subset of breast cancer cell lines. Cancer Res 2004;64:5132-9.
8. Lomnytska M, Dubrovska A, Hellman U, Volodko N, Souchelnytskyi S. Increased expression of cSHMT, Tbx3 and utrophin in plasma of ovarian and breast cancer patients. Int J Cancer 2006;118:412-21.
9. Carlson H, Ota S, Song Y, Chen Y, Hurlin PJ. Tbx3 impinges on the p53 pathway to suppress apoptosis, facilitate cell transformation and block myogenic differentiation. Oncogene 2002;21:3827-35.
10. Lingbeek ME, Jacobs JJ, van Lohuizen M. The T-box repressors TBX2 and TBX3 specifically regulate the tumor suppressor gene p14ARF via a variant T-site in the initiator. J Biol Chem 2002;277:26120-7.
11. Brummelkamp TR, Kortlever RM, Lingbeek M, et al. TBX-3, the gene mutated in Ulnar-Mammary Syndrome, is a negative regulator of p19ARF and inhibits senescence. J Biol Chem 2002;277:6567-72.
12. Leake R, Barnes D, Pinder S, et al. Immunohistochemical detection of steroid receptors in breast cancer: a working protocol. UK Receptor Group, UK NEQAS, The Scottish Breast Cancer Pathology Group, and The Receptor and Biomarker Study Group of the EORTC. J Clin Pathol 2000;53:634-5.
13. Ito A, Asamoto M, Hokaiwado N, Takahashi S, Shirai T. Tbx3 expression is related to apoptosis and cell proliferation in rat bladder both hyperplastic epithelial cells and carcinoma cells. Cancer Lett 2005;219:105-12.
14. Renard CA, Labalette C, Armengol C, et al. Tbx3 is a downstream target of the Wnt/β-catenin pathway and a critical mediator of {β}-catenin survival functions in liver cancer. Cancer Res 2007;67:901-10.
15. Verdone L, Caserta M, Di Mauro E. Role of histone acetylation in the control of gene expression. Biochem Cell Biol 2005;83:344-53.
16. Glozak MA, Sengupta N, Zhang X, Seto E. Acetylation and deacetylation of non-histone proteins. Gene 2005;363:15-23.
17. Cress WD, Seto E. Histone deacetylases, transcriptional control, and cancer. J Cell Physiol 2000;184:1-16.
18. Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene 2007;26:5420-32.
19. Zhang Z, Yamashita H, Toyama T, et al. Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*. Breast Cancer Res Treat 2005;94:11-6.
20. Matheu A, Klatt P, Serrano M. Regulation of the INK4a/ARF locus by histone deacetylase inhibitors. J Biol Chem 2005;280:42433-41.
21. Vance KW, Carreira S, Brosch G, Goding CR. Tbx2 is overexpressed and plays an important role in maintaining proliferation and suppression of senescence in melanomas. Cancer Res 2005;65:2260-8.
22. Sasaki T, Ryo A, Uemura H, et al. An immunohistochemical scoring system of prolyl isomerase Pin1 for predicting relapse of prastate carcinoma after radical prostatectomy. Pathol Res Pract 2006;202:357-64.
23. Keyomarsi K, Tucker SL, Buchholz TA, et al. Cyclin E and survival in patients with breast cancer. N Engl J Med 2002;347:1566-75.
24. Sun G, Lewis LE, Huang X, Nguyen Q, Price C, Huang T. TBX5, a gene mutated in Holt-Oram syndrome, is regulated through a GC box and T-box binding elements (TBEs). J Cell Biochem 2004;92:189-99.
25. Dokmanovic M, Marks PA. Prospects: histone deacetylase inhibitors. J Cell Biochem 2005;96:293-304.
26. Puri PL, Iezzi S, Stiegler P, et al. Class I histone deacetylases sequentially interact with MyoD and pRb during skeletal myogenesis. Mol Cell 2001;8:885-97.
27. Zhang X, Ozawa Y, Lee H, et al. Histone deacetylase 3 (HDAC3) activity is regulated by interaction with protein serine/threonine phosphatase 4. Genes Dev 2005;19:827-39.
28. Mei S, Ho AD, Mahlknecht U. Role of histone deacetylase inhibitors in the treatment of cancer [review]. Int J Oncol 2004;25:1509-19.